Piper Sandler Trims bluebird bio (NASDAQ:BLUE) Target Price to

bluebird bio (NASDAQ:BLUE) had its target price lowered by equities researchers at Piper Sandler from to in a note issued to investors on Thursday, The Fly reports.

Other equities analysts have also issued reports about the stock. Canaccord Genuity dropped their price objective on shares of bluebird bio from $171.00 to $118.00 and set a “buy” rating on the stock in a research report on Monday, December 9th. Zacks Investment Research lowered shares of bluebird bio from a “buy” rating to a “hold” rating and set a $87.00 price objective on the stock. in a research report on Friday, February 21st. Bank of America started coverage on shares of bluebird bio in a research report on Monday, February 3rd. They issued a “buy” rating and a $120.00 price objective on the stock. Wells Fargo & Co reissued a “buy” rating on shares of bluebird bio in a research report on Thursday. Finally, Oppenheimer dropped their price objective on shares of bluebird bio from to in a research report on Thursday, February 20th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $124.94.

Shares of BLUE traded down $0.75 during trading hours on Thursday, hitting $46.57. The company had a trading volume of 1,184,825 shares, compared to its average volume of 972,912. The firm has a market cap of $2.49 billion, a price-to-earnings ratio of -3.25 and a beta of 2.36. The business has a fifty day moving average of $70.24 and a 200-day moving average of $83.66. bluebird bio has a 12 month low of $38.95 and a 12 month high of $163.43. The company has a quick ratio of 5.15, a current ratio of 5.15 and a debt-to-equity ratio of 0.13.

bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings data on Tuesday, February 18th. The biotechnology company reported ($4.04) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($3.79) by ($0.25). The company had revenue of $10.00 million during the quarter, compared to the consensus estimate of $8.23 million. bluebird bio had a negative net margin of 1,767.49% and a negative return on equity of 51.23%. bluebird bio’s revenue for the quarter was down 47.9% compared to the same quarter last year. During the same period in the previous year, the company earned ($2.72) earnings per share. On average, equities analysts expect that bluebird bio will post -15.64 EPS for the current fiscal year.

In other bluebird bio news, CFO William D. Baird III sold 1,254 shares of the stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $90.60, for a total transaction of $113,612.40. Following the sale, the chief financial officer now directly owns 13,746 shares in the company, valued at $1,245,387.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Alison Cecily Finger sold 517 shares of the stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $84.96, for a total transaction of $43,924.32. The disclosure for this sale can be found here. Insiders have sold 12,784 shares of company stock worth $1,149,985 over the last quarter. Corporate insiders own 3.00% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the business. Whittier Trust Co. boosted its stake in shares of bluebird bio by 36.5% in the 4th quarter. Whittier Trust Co. now owns 542 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 145 shares in the last quarter. SG Americas Securities LLC boosted its stake in shares of bluebird bio by 15.1% in the 4th quarter. SG Americas Securities LLC now owns 1,551 shares of the biotechnology company’s stock valued at $136,000 after purchasing an additional 203 shares in the last quarter. California State Teachers Retirement System boosted its stake in shares of bluebird bio by 0.3% in the 3rd quarter. California State Teachers Retirement System now owns 87,794 shares of the biotechnology company’s stock valued at $8,061,000 after purchasing an additional 238 shares in the last quarter. Great West Life Assurance Co. Can boosted its stake in shares of bluebird bio by 7.6% in the 4th quarter. Great West Life Assurance Co. Can now owns 3,880 shares of the biotechnology company’s stock valued at $338,000 after purchasing an additional 275 shares in the last quarter. Finally, Stifel Financial Corp boosted its stake in shares of bluebird bio by 4.5% in the 4th quarter. Stifel Financial Corp now owns 7,137 shares of the biotechnology company’s stock valued at $624,000 after purchasing an additional 308 shares in the last quarter.

About bluebird bio

bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder.

Featured Story: What is meant by a buy rating?

The Fly

Analyst Recommendations for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.